Switch to mania after ayahuasca consumption in a man with bipolar disorder : a case report Alejandro G Szmulewicz, Marina P Valerio and Jose M Smith International Journal of Bipolar Disorders, 2015, 3, (4), 1-3. DOI 10.1186/s40345-014-0020-y Abstract Background : There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing evidence for the antidepressant properties of its components. However, there are no reports on the effects of this substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor. Case report : We present the case of [...]
Lire la suitePsilocybine mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects SMIGIELSKI Lukasz, SCHEIDEGGER Milan, KOMETER Michael, VOLLENWEIDER Franz X. NeuroImage, 2019, 196, 207-215 Doi : 10.1016/j.neuroimage.2019.04.009 A B S T R A C T Both psychedelics and meditation exert profound modulatory effects on consciousness, perception and cognition, but their combined, possibly synergistic effects on neurobiology are unknown. Accordingly, we conducted a randomized, double-blind, placebo-controlled study with 38 participants following a single administration of the psychedelic psilocybin (315 μg/kg p.o.) during a 5-day mindfulness retreat. Brain dynamics were quantified directly pre- and post-intervention by functional magnetic resonance imaging during the resting state and [...]
Lire la suiteConsideration of Ayahuasca for the Treatment of Post-traumatic Stress Disorder Jessica L. NIELSON, & Julie D. MEGLER MAPS Bulletin Annual Report, Winter 2012, 29-31. THERE IS A GROWING AMOUNT OF RESEARCH on the development of PTSD and its various treatments. The fact that many people who su!er from PTSD struggle with the currently approved therapeutic options that are available to them suggests that we need to start exploring alternative strategies to treat this disorder.1 With the large number of veterans returning home from war that may have or will develop PTSD, we must have a diverse framework of therapy and integration in place [...]
Lire la suitePsilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers Boris B Quednow, Michael Kometer, Mark A Geyer and Franz X Vollenweider Neuropsychopharmacology, 2012, 37, 630–640 doi:10.1038/npp.2011.228 The serotonin-2A receptor (5-HT2AR) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients. The hallucinogen psilocybin disrupts automatic forms of sensorimotor gating and response inhibition in humans, but it is unclear so far whether the 5-HT2AR or 5-HT1AR agonist properties of its bioactive metabolite psilocin account for these effects. Thus, we investigated whether psilocybin-induced deficits in automatic and controlled inhibition in healthy [...]
Lire la suiteIntegrating Psychedelic Medicines and Psychiatry : Theory and Methods of a Model Clinic Jordan Sloshower Chapter 7, In : Labate B., Cavnar C. (eds) : Plant Medicines, Healing and Psychedelic Science, 2018 © Springer International Publishing AG 2018 DOI: 10.1007/978-3-319-76720-8_7 Abstract The past two decades has seen a significant increase in both popular and scientific interest in psychedelic substances and plants as therapeutics for mental illness, addictions, and psychospiritual suffering. Current psychiatric practice privileges a biological paradigm in which the brain is considered the locus of mental illness and symptom-focused treatments are delivered to patients as passive recipients. In contrast, a psychedelic healing paradigm, constructed through [...]
Lire la suitePsychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum Theodore GREINER, Neil R. BURCH, Robert EDELBERG AMA, Archives of Neurology & Psychiatry, 1958, 79, (2), 208-210. doi:10.1001/archneurpsyc.1958.02340020088016 Abstract Despite 14 years of investigation, as intensive as accorded any biologically active chemical, a gap remains in the systematic description of human response to lysergic acid diethylamide (LSD-25). The dramatic schizophrenic-like symptoms after doses of 40 μg to 100 μg have drawn the main interest. The threshold for activity is placed at 20 μg by general consensus, while perfunctory administration of smaller doses has left their effect uncertain. Accompanying those pharmacologic demonstrations has been [...]
Lire la suitePsycholytic and Psychedelic Therapy Research 1931-1995 : Introduction (A Complete International Bibliography) Torsten PASSIE Laurentius Publishers, Hannover, Germany, 1997 1 . INTRODUCTION "The future may teach us to exercise a direct influence, by means of particular chemical substances, on the amounts of energy and their distribution in the mental apparatus. It may be that there are other still undreamt of possibilities of therapy" . Sigmund Freud The present bibliography includes nearly all publications on the psychotherapeutic treatment procedures which are referred to as "psycholytic" or "psychedelic" therapy and their foundations. The methods in question use the psychic activating properties of specific substances to reinforce psychotherapeutic treatments. Some appropriate [...]
Lire la suiteSub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution M. V. Uthaug, K. van Oorsouw, K. P. C. Kuypers, M. van Boxtel, N. J. Broers, N. L. Mason, S. W. Toennes, J. Riba, J. G. Ramaekers Psychopharmacology, 2018 https://doi.org/10.1007/s00213-018-4988-3 Abstract Rationale : Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on [...]
Lire la suiteSurvey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]
Lire la suiteMystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later Roland R. Griffiths ,W.A. Richards , Matthew W. Johnson, Una D. McCann, R. Jesse Journal of Psychopharmacology, 2008, 1–12. Doi : 10.1177/0269881108094300 Abstract Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to data obtained at screening and on drug session days. Participants were 36 hallucinogen-naïve adults [...]
Lire la suite